Login
$VSTM
$7.73 +$0.03 (0.39%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Joined 2025 pay Source
Daniel W. Paterson Also a director
President, Chief Executive Officer
64 Not stated 2012 $2,349,975
Daniel Calkins
Chief Financial Officer
38 Since 2023
3 years
2018 $976,871
Michael Kauffman Also a director
President of Development
62 Since 2025
1 year
Not stated $272,993

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
10
serving now
Independent
1 of 4
stated in the proxy; 6 not stated
Average tenure
6.4 years
from year joined
Director Age On board Independent Committees Other public boards 2025 pay Source
Daniel Paterson
65 2023
3 years
Not independent None stated None stated Paid as CEO
John Johnson
68 2020
6 years
Independent
Compensation Committee · Chair Nominating and Corporate Governance Committee · Chair
Axogen Inc., Xeris Biopharma Holdings, Inc. $199,993
Michael Kauffman
62 2012
14 years
Not independent
Research and Development Committee
Kezar Biosciences Not stated
Brian Stuglik
66 2017
9 years
Not independent
Commercialization Committee · Chair
Oncopeptides AB $202,993
Karin Tollefson
59 2023
3 years
Not stated
Audit Committee Nominating and Corporate Governance Committee Commercialization Committee
None stated Not stated
Paul Bunn
81 2021
5 years
Not stated
Research and Development Committee
None stated $192,993
Anil Kapur
57 2022
4 years
Not stated
Audit Committee Compensation Committee Commercialization Committee
Nurix Therapeutics, Inc. $209,993
Michelle Robertson
59 2021
5 years
Not stated
Audit Committee · Chair Compensation Committee
None stated $202,993
Eric Rowinsky
69 2017
9 years
Not stated
Research and Development Committee · Chair Nominating and Corporate Governance Committee
Biogen Idec, Inc., Fortress Biotech, Inc., Purple Biotech Ltd. $214,993
Robert Gagnon Leaving at the meeting
Not stated Not stated Not stated None stated None stated $182,993
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

We could not read related-party transactions reliably

Rather than show a list that might be incomplete, we show nothing. They are in the proxy filed Apr 9, 2026, in its related person transactions section.

Read them in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support